Healthcare
PharmaCyte Biotech, Inc.(PMCB)
Live Price
Offline$0.7178
-8.82% today
1Y Change
-29.24%
Window
Jun 23, 2025 โ Jun 11, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +277.2%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 23, 2025 โ Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PharmaCyte Biotech, Inc. (PMCB) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.72 and down 29.2% across the available one-year price window (Jun 23, 2025 โ Jun 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +277.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +277.2%, free cash flow -38.4% with operating margin 0.0% and ROIC -9.9%. Stock Foundry combines PMCB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Mar 17, 2026 with an EPS surprise of +316.7%.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +277.2%, while operating margin sits near 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 1, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 17, 2026 | +316.7% | +1.4% | +13.0% | +10.4% |
2025 Dec 18, 2025 | โ | +2.1% | -15.5% | +4.2% |
2025 Sep 15, 2025 | โ | -1.9% | -2.9% | -2.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMCB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PMCB Max Drawdown
-46.66%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PMCB and SPY.
Company Overview
PharmaCyte Biotech, Inc.
NASDAQ Capital Market
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
- Leadership
- Joshua N. Silverman
- IPO Date
- Jan 2, 2013
- Employees
- 2
- Street Address
- 3960 Howard Hughes Parkway
- Mailing
- Las Vegas, NV, 89169
- Region
- Las Vegas, NV, US
- Reporting Currency
- USD
- Investor Line
- 917 595 2850
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 1.2
- Price/Sales
- โ
- Price/Book
- 0.2
Growth
- Revenue
- 0.0%
- EPS
- +277.2%
- Free Cash Flow
- -38.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -7.7%
- ROIC
- -9.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 12.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.